Literature DB >> 14633963

Treatment of hepatitis C. The 2002 French consensus.

D Dhumeaux1, P Marcellin, E Lerebours.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 14633963      PMCID： PMC1773901          DOI： 10.1136/gut.52.12.1784

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  25 in total

Review 1.  EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999. Consensus statement.

Authors: 
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

2.  A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

Authors:  K L Lindsay; C Trepo; T Heintges; M L Shiffman; S C Gordon; J C Hoefs; E R Schiff; Z D Goodman; M Laughlin; R Yao; J K Albrecht
Journal:  Hepatology       Date:  2001-08       Impact factor: 17.425

Review 3.  Hepatitis C virus infection in Eastern Europe.

Authors:  N V Naoumov
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

Review 4.  Natural history of hepatitis C.

Authors:  A Alberti; L Chemello; L Benvegnù
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

Review 5.  Hepatitis C: the clinical spectrum of the disease.

Authors:  P Marcellin
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

Review 6.  Hepatitis C virus infection: quality of life and side effects of treatment.

Authors:  G R Foster
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

Review 7.  Hepatitis C virus infection in Western Europe.

Authors:  C Trépo; P Pradat
Journal:  J Hepatol       Date:  1999       Impact factor: 25.083

8.  Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

Authors:  E J Heathcote; M L Shiffman; W G Cooksley; G M Dusheiko; S S Lee; L Balart; R Reindollar; R K Reddy; T L Wright; A Lin; J Hoffman; J De Pamphilis
Journal:  N Engl J Med       Date:  2000-12-07       Impact factor: 91.245

9.  Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study.

Authors:  F Imbert-Bismut; V Ratziu; L Pieroni; F Charlotte; Y Benhamou; T Poynard
Journal:  Lancet       Date:  2001-04-07       Impact factor: 79.321

10.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321
View more
  8 in total

1.  Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment.

Authors:  Hela Elloumi; Fatma Houissa; Najet-Bel Hadj; Dalila Gargouri; Malika Romani; Jamel Kharrat; Abdeljabbar Ghorbel
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

2.  The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010.

Authors:  Marc-Arthur Loko; Dominique Salmon; Patrizia Carrieri; Maria Winnock; Marion Mora; Laurence Merchadou; Stéphanie Gillet; Elodie Pambrun; Jean Delaune; Marc-Antoine Valantin; Isabelle Poizot-Martin; Didier Neau; Philippe Bonnard; Eric Rosenthal; Karl Barange; Philippe Morlat; Karine Lacombe; Anne Gervais; François Rouges; Alain Bicart See; Caroline Lascoux-Combe; Daniel Vittecoq; Cécile Goujard; Claudine Duvivier; Bruno Spire; Jacques Izopet; Philippe Sogni; Lawrence Serfaty; Yves Benhamou; Firouzé Bani-Sadr; François Dabis
Journal:  BMC Infect Dis       Date:  2010-10-22       Impact factor: 3.090

3.  Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.

Authors:  Christopher Payan; Adeline Pivert; Patrice Morand; Samira Fafi-Kremer; Fabrice Carrat; Stanislas Pol; Patrice Cacoub; Christian Perronne; Françoise Lunel
Journal:  Gut       Date:  2007-03-15       Impact factor: 23.059

4.  Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience.

Authors:  Rafie Yakoob; Issam Al Bozom; Ragesh Babu Thandassery; Mohamed Osman Abdel Rahman; Moutaz F Derbala; Muneera J Al Mohannadi; Anil K John; Manik Sharma; Hamidulla Wani; Saad Al Kaabi
Journal:  Ann Gastroenterol       Date:  2015 Apr-Jun

5.  Hepatitis C Virus Increases Free Fatty Acids Absorption and Promotes its Replication Via Down-Regulating GADD45α Expression.

Authors:  Wei Chen; Xiao-Ming Li; An-Ling Li; Gui Yang; Han-Ning Hu
Journal:  Med Sci Monit       Date:  2016-07-06

6.  Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin.

Authors:  Roberto J Carvalho-Filho; Olav Dalgard
Journal:  Pharmgenomics Pers Med       Date:  2010-03-11

7.  Influence of healthcare-associated factors on the efficacy of hepatitis C therapy.

Authors:  Mohamed A Daw; Aghynya A Dau; Mohamed M Agnan
Journal:  ScientificWorldJournal       Date:  2012-12-27

8.  Continuum of hepatitis C care in France: A 20-year cohort study.

Authors:  Coralie Hermetet; Frederic Dubois; Catherine Gaudy-Graffin; Yannick Bacq; Bernard Royer; Christophe Gaborit; Louis D'Alteroche; Jean Claude Desenclos; Philippe Roingeard; Leslie Grammatico-Guillon
Journal:  PLoS One       Date:  2017-08-29       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.